CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle and gene expression.
• (R)-roscovitine and (S)-CR8 are known CDK inhibitors with potential anti-cancer applications.
• Neuroblastoma, particularly MYCN-amplified types, presents a significant challenge in pediatric oncology.

Purpose of the Study:

• To elucidate the precise molecular mechanisms of action for (R)-roscovitine and (S)-CR8.
• To identify the direct kinase targets of these inhibitors.
• To investigate their impact on gene expression and transcription in neuroblastoma cells.

Main Methods:

• Application of multi-omics techniques including kinase interaction assays, affinity chromatography, transcriptomics, and proteomics.
• Utilized human neuroblastoma cell lines (SH-SY5Y, IMR32) and in vivo xenograft models.
• Quantitative PCR and Western blot analyses were performed for specific protein and gene validation.

Main Results:

• Identified direct targets belonging to CDK, DYRK, CLK, and CK1 kinase families.
• Inhibition of CDK7, CDK9, and CDK12 led to reduced RNA polymerase II activity and gene downregulation.
• Demonstrated significant downregulation of MYC transcription factors, including MYCN, in neuroblastoma models.

Conclusions:

• The study reveals a dual mechanism of action for (R)-roscovitine and (S)-CR8 involving CDK inhibition and MYC downregulation.
• These findings highlight the therapeutic potential of these kinase inhibitors for MYC-dependent cancers, especially high-risk neuroblastoma.
• Targeting MYCN through CDK inhibition offers a promising strategy for neuroblastoma treatment.